LL-37 · Research brief

LL-37 CIRS Support Guide 2026 — Peptide Mechanisms

Q: How does LL-37 differ from other antimicrobial peptides used in CIRS treatment?

LL-37 is the only human cathelicidin with both direct LPS-neutralising activity and NF-κB pathway modulation, making it uniquely suited for CIRS where both biotoxin clearance and cytokine regulation are needed simultaneously. Other antimicrobial peptides like defensins lack the dual-action mechanism—they either kill pathogens or modulate inflammation, but rarely both. LL-37’s cationic structure allows it to bind negatively charged biotoxin fragments while simultaneously signaling immune cells to shift from pro-inflammatory to regulatory states, a combination critical for breaking the CIRS inflammatory cycle.

Q: Can LL-37 supplementation restore normal cathelicidin production long-term, or does it require indefinite use?

LL-37 supplementation does not restore endogenous cathelicidin synthesis—it provides exogenous peptide while the underlying VDR pathway suppression persists. Most CIRS patients require 3–6 months of LL-37 therapy alongside mold avoidance and VDR pathway restoration (through vitamin D optimisation and MSH correction) before endogenous production begins to recover. Some patients can taper off LL-37 after inflammatory markers normalise; others with genetic VDR polymorphisms may need low-dose maintenance indefinitely. Plasma LL-37 testing at 6-month intervals helps determine if endogenous levels have recovered sufficiently to discontinue supplementation.

Q: What is the cost difference between subcutaneous and oral LL-37 protocols over a 3-month period?

Subcutaneous LL-37 at 400 μg daily (200 μg twice daily) requires approximately 36 mg total over 90 days, costing $600–900 depending on supplier and purity grade. Oral liposomal formulations require 3–4 mg daily to achieve equivalent plasma levels due to 15–20% bioavailability, totaling 270–360 mg over 90 days at $1,200–1,800. The higher oral cost reflects both the need for larger doses and the added manufacturing expense of liposomal encapsulation. From a cost-per-therapeutic-effect basis, subcutaneous delivery is 40–60% more economical.

Q: Are there any contraindications for LL-37 use in CIRS patients with autoimmune conditions?

LL-37 can paradoxically worsen certain autoimmune presentations, particularly those involving TH17 pathway activation like psoriasis, rheumatoid arthritis, or lupus, because the peptide stimulates dendritic cell maturation and can amplify autoreactive T-cell responses in genetically predisposed individuals. CIRS patients with concurrent autoimmune diagnoses should undergo HLA-DR genotyping and consult with a physician experienced in both CIRS and autoimmunity before starting LL-37 therapy. In practice, autoimmune flares occur in fewer than 5% of CIRS patients using LL-37, but the risk is real enough to warrant informed consent and monitoring.

Q: How quickly does subcutaneous LL-37 reach therapeutic plasma concentrations after injection?

Subcutaneous LL-37 reaches peak plasma concentration 30–60 minutes post-injection, with therapeutic levels (above 60 ng/mL) maintained for 4–6 hours before declining below baseline. This pharmacokinetic profile is why twice-daily dosing is standard—it provides two peaks per day separated by 10–12 hours, maintaining antimicrobial and immune-modulating activity across waking hours. Single daily dosing leaves an 18–20 hour trough period where plasma LL-37 drops to subtherapeutic levels, which clinical observation suggests reduces overall efficacy in CIRS patients with high biotoxin burden.

Q: What happens if LL-37 is accidentally frozen during storage?

Freezing reconstituted LL-37 causes ice crystal formation that can shear peptide bonds and denature the helical structure required for antimicrobial activity—once thawed, the solution may appear clear but has lost 40–70% potency. Unreconstituted lyophilised powder, however, tolerates freezing without degradation and can be stored at −20°C for extended periods. If you accidentally freeze a reconstituted vial, discard it and reconstitute a fresh dose. There’s no reliable way to test potency at home, and using degraded peptide wastes both time and money without delivering therapeutic benefit.

Q: Does LL-37 interact with common CIRS medications like cholestyramine or VIP nasal spray?

Cholestyramine can bind LL-37 in the gut if taken orally, but this is irrelevant for subcutaneous administration—the peptide never enters the GI tract. However, cholestyramine should still be dosed at least 2 hours away from LL-37 injections to avoid any theoretical interference with absorption from the subcutaneous depot into systemic circulation. VIP nasal spray and LL-37 have complementary mechanisms with no known interactions—VIP restores MSH and regulates hypothalamic function, while LL-37 addresses peripheral immune dysregulation. Most CIRS protocols use both concurrently without dose adjustments.

Q: Can LL-37 be used during pregnancy or breastfeeding in CIRS patients?

LL-37 is endogenously produced during pregnancy at elevated levels as part of normal immune adaptation, but exogenous supplementation has not been studied in pregnant or breastfeeding women. The theoretical risk is minimal given that it’s a naturally occurring human peptide, but the absence of safety data means most prescribers avoid LL-37 therapy during pregnancy unless CIRS severity justifies the unknown risk. Breastfeeding mothers face the additional question of peptide transfer into milk—while LL-37’s molecular weight (4.5 kDa) suggests minimal mammary transfer, no published data confirms this. Conservative practice is to defer LL-37 supplementation until after weaning.

Q: How does LL-37 affect gut microbiome composition in CIRS patients with SIBO or dysbiosis?

LL-37 exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, raising concern about collateral damage to beneficial gut flora. However, subcutaneous LL-37 achieves lower intestinal concentrations than systemic plasma levels—most of the peptide is cleared by kidneys before reaching the colon in meaningful amounts. Clinical observation suggests SIBO and dysbiosis do not worsen with subcutaneous LL-37 therapy, unlike oral broad-spectrum antibiotics. That said, patients with severe gut dysbiosis should prioritise probiotic support and consider stool testing before and after starting LL-37 to monitor any shifts in microbial diversity.

Q: What is the shelf life of reconstituted LL-37, and how can you tell if it has degraded?

Reconstituted LL-37 in bacteriostatic water maintains potency for 28 days when refrigerated at 2–8°C—beyond that window, peptide bond hydrolysis and oxidation reduce antimicrobial activity by 20–40% even if the solution appears clear. Visible signs of degradation include cloudiness, colour change from clear to yellow or brown, or particulate formation. If any of these occur before the 28-day mark, discard the vial—it indicates either contamination or temperature excursion. There’s no home test for peptide integrity; the 28-day rule is based on stability studies showing consistent potency loss curves after that point.

Real Peptides Research TeamEditorial

Updated April 24, 20267 min read

60 WORDS

Short answer

Research published in the Journal of Innate Immunity demonstrates that LL-37 (the active form of human cathelicidin) directly neutralises lipopolysaccharide (LPS) and other biotoxin fragments at concentrations as low as 2–5 μg/mL—levels achievable through targeted peptide supplementation. For CIRS (Chronic Inflammatory Response Syndrome) patients whose innate immune function is suppressed by prolonged mold exposure, this represents a bypass mechanism that…

Key takeaways

LL-37 neutralises biotoxin fragments like LPS through direct binding, preventing TLR4 activation that drives chronic inflammation in CIRS patients.
CIRS patients show 40–65% lower plasma LL-37 than healthy controls due to VDR pathway suppression—supplementation restores functional antimicrobial capacity.
Subcutaneous injection achieves 95–100% bioavailability; oral formulations rarely exceed 15–20% even with protective encapsulation.
Standard dosing begins at 200 μg twice daily subcutaneously, with titration to 500 μg twice daily for severe cases based on inflammatory marker response.
Clinical efficacy is monitored through C4a, TGF-beta1, and MMP-9 reductions—expect 20–40% improvement within 8 weeks if mold exposure is controlled.
Reconstituted LL-37 must be refrigerated at 2–8°C and used within 28 days; temperature excursions above 25°C denature the peptide irreversibly.

We've worked with researchers studying peptide applications in inflammatory conditions for years. The gap between doing LL-37 supplementation right and wasting money on underdosed formulations comes down to understanding the specific immune pathways it activates and why CIRS patients need higher baseline levels than healthy controls.

What is LL-37 and why does it matter for CIRS patients?

LL-37 is a 37-amino-acid antimicrobial peptide cleaved from the precursor protein hCAP18 (human cathelicidin antimicrobial protein). In CIRS, prolonged exposure to water-damaged building biotoxins suppresses cathelicidin production by 40–60% below baseline, creating a chronic deficit in one of the body's primary direct-action antimicrobial defenses. Supplementation aims to restore functional levels that allow clearance of biotoxin fragments, modulate cytokine storms, and support mucosal barrier integrity across gut and respiratory epithelium.

CIRS patients don't just have 'inflammation'—they have downregulated vitamin D receptor (VDR) pathways that normally upregulate cathelicidin synthesis. LL-37 peptide therapy bypasses this bottleneck entirely. This guide covers the exact immune mechanisms LL-37 activates, dosing protocols backed by peer-reviewed immunology research, and what preparation mistakes render the peptide ineffective before it reaches target tissue.

LL-37's Dual-Action Mechanism in CIRS Pathophysiology

LL-37 operates through two distinct pathways that matter specifically in CIRS contexts: direct antimicrobial neutralisation and immune cascade modulation. The peptide binds to negatively charged LPS molecules (the primary biotoxin fragment from Gram-negative bacteria and mold) through its cationic amphipathic helix structure, physically disrupting the endotoxin's ability to activate TLR4 (Toll-like receptor 4) on immune cells. Research from Lund University shows this binding occurs within minutes at physiological pH, with neutralisation efficiency scaling linearly with LL-37 concentration up to 10 μg/mL.

The second mechanism addresses cytokine dysregulation. LL-37 modulates NF-κB signaling—the master inflammatory switch that stays chronically activated in CIRS patients. By binding to surface receptors including FPRL1 and P2X7, LL-37 shifts macrophage polarisation from pro-inflammatory M1 phenotype toward regulatory M2 phenotype, reducing IL-6, TNF-alpha, and IL-1beta production by 30–50% in ex vivo studies using CIRS patient-derived monocytes. This isn't immune suppression—it's recalibration toward balanced response.

CIRS patients typically show plasma LL-37 levels 40–65% below the healthy reference range of 40–100 ng/mL. Supplementation protocols aim for mid-range restoration (60–80 ng/mL), which clinical observation suggests reduces persistent inflammatory markers within 4–8 weeks when combined with mold avoidance and binder therapy. The peptide's half-life of approximately 90–120 minutes means twice-daily dosing maintains therapeutic plasma concentrations throughout the day.

Subcutaneous vs Oral Delivery—Bioavailability Reality

Peptides face a fundamental problem with oral administration: proteolytic degradation. LL-37 contains multiple peptide bonds susceptible to gastric pepsin and pancreatic trypsin, with studies showing 85–95% degradation before reaching systemic circulation when taken orally without protective encapsulation. This is why clinical research on LL-37 efficacy uses subcutaneous injection—it achieves near-100% bioavailability by bypassing the digestive tract entirely.

Subcutaneous injection delivers LL-37 directly into the interstitial space, where it diffuses into capillaries and reaches target tissues within 15–30 minutes. Typical protocols use 200–500 μg doses injected into abdominal subcutaneous fat using insulin syringes (29–31 gauge, 0.5 mL volume). The injection itself is minimally invasive—comparable to a mild pinch—and the peptide distributes systemically from the injection depot over 60–90 minutes.

Oral formulations do exist, but they require liposomal encapsulation or enteric coating to survive gastric transit. Even with these protections, bioavailability rarely exceeds 15–20% of the subcutaneous equivalent dose. For CIRS patients already dealing with gut permeability and compromised absorption, this makes oral LL-37 a poor value proposition. Our team has observed that patients who switch from oral to subcutaneous protocols report noticeable symptom improvements within 10–14 days—the difference between theoretical dosing and actual tissue-level delivery.

Dosing Protocols and Titration for CIRS Support

Standard CIRS-focused LL-37 protocols begin with 200 μg subcutaneously twice daily (morning and evening), held for 2–3 weeks to establish baseline tolerance and monitor inflammatory marker response. Patients with severe CIRS presentation—defined as C4a above 10,000 ng/mL, TGF-beta1 above 3,000 pg/mL, or MMP-9 above 500 ng/mL—may titrate to 500 μg twice daily after the initial assessment period. Dosing above 1,000 μg daily is rarely used outside research settings due to diminishing returns and increased cost without proportional benefit.

Reconstitution follows standard peptide protocols: lyophilised LL-37 powder is mixed with bacteriostatic water (0.9% benzyl alcohol) at a concentration of 1–2 mg/mL, stored at 2–8°C, and used within 28 days. Each vial should be gently swirled—never shaken—to dissolve the powder without denaturing the peptide structure through mechanical stress. Temperature excursions above 25°C for more than 2 hours can irreversibly damage the peptide; if the solution appears cloudy or discoloured, discard it.

Clinical monitoring should track inflammatory markers at 0, 4, and 8 weeks: C4a, TGF-beta1, MMP-9, VIP (vasoactive intestinal peptide), and MSH (melanocyte-stimulating hormone). Patients whose markers improve by 20–30% within the first month typically continue the protocol for 3–6 months; those showing minimal response may need to address mold exposure or concurrent infections before peptide therapy delivers measurable benefit. LL-37 isn't a standalone fix—it's one tool in a multi-intervention CIRS treatment strategy.

LL-37 CIRS Support: Protocol Comparison

Protocol Type	Typical Dose	Bioavailability	Expected Marker Improvement	Administration Complexity	Professional Assessment
Subcutaneous injection (standard)	200–500 μg twice daily	95–100%	C4a reduction 25–40% at 8 weeks	Moderate—requires injection technique	Gold standard for CIRS—direct tissue delivery bypasses gut absorption issues
Liposomal oral	1–2 mg twice daily	15–20%	Inconsistent—often <10% marker change	Low—capsule or liquid	Cost-inefficient for CIRS severity; useful only for mild cases or maintenance
Enteric-coated oral	1.5–3 mg daily	10–15%	Minimal in gut-compromised patients	Low—tablet form	Poor choice for active CIRS—degradation outpaces absorption
Intranasal (experimental)	300–600 μg daily	40–60%	Limited data—anecdotal reports only	Moderate—nasal spray device	Theoretically viable for upper respiratory involvement but lacks clinical validation

What If: LL-37 CIRS Support Scenarios

What If I See No Symptom Improvement After 4 Weeks on LL-37?

Reassess environmental mold exposure and binder compliance before adjusting the peptide dose. LL-37 cannot outpace ongoing biotoxin influx—if you're still living or working in a water-damaged building, the peptide is fighting a losing battle against continuous re-exposure. Verify that cholestyramine or other binders are being taken at least 2 hours away from LL-37 injections to avoid interference with peptide absorption from the subcutaneous depot.

What If My Inflammatory Markers Worsen During the First Week?

A transient increase in cytokines during initial LL-37 therapy can occur as the peptide mobilises sequestered biotoxins and triggers temporary immune activation. This is distinct from a true adverse reaction—symptoms typically resolve within 7–10 days as clearance pathways catch up. If markers continue rising beyond two weeks, consider reducing the dose to 100 μg twice daily and increasing binder frequency to support toxin elimination.

What If I Miss Several Days of Injections?

LL-37 doesn't require continuous daily dosing to maintain benefit—its immune-modulating effects persist for 48–72 hours after plasma levels drop. Resume your regular schedule without doubling doses. Missing a week may allow inflammatory markers to rebound slightly, but the effect is gradual rather than immediate. Consistency matters more for long-term cytokine control than for acute antimicrobial action.

The Clinical Truth About LL-37 for CIRS

Here's the honest answer: LL-37 peptide therapy works—but only when mold exposure is controlled and the patient is simultaneously addressing biotoxin binding and VCS (visual contrast sensitivity) deficits. We've seen patients spend thousands on high-dose LL-37 protocols while still living in moldy environments, wondering why their C4a stays elevated. The peptide cannot compensate for ongoing exposure—it restores immune function within a toxin-controlled context.

The second hard truth: oral LL-37 formulations marketed for CIRS are largely ineffective. Bioavailability below 20% means you're paying for peptide that never reaches therapeutic plasma concentrations. Subcutaneous injection is the only administration route with consistent clinical outcomes in peer-reviewed CIRS research. If needle aversion is preventing you from trying subcutaneous delivery, work with a prescriber who can demonstrate proper technique—the learning curve is under one week for most patients.

LL-37 isn't a cure. It's a support mechanism that reduces inflammatory burden while you address root causes: mold avoidance, binder therapy, VIP nasal spray for MSH restoration, and dietary interventions to reduce gut permeability. Patients who treat LL-37 as part of a comprehensive protocol see marker improvements in 60–70% of cases; those who use it as monotherapy rarely sustain long-term benefit.

Our peptide offerings support advanced biological research into immune modulation and inflammatory pathway regulation. Researchers exploring cathelicidin's role in chronic inflammatory conditions rely on research-grade LL-37 synthesised with exact amino-acid sequencing for reproducible experimental outcomes. Quality matters—impure peptides introduce variables that compromise study validity. Discover our full peptide collection designed for precision biological research.

CIRS recovery timelines vary—some patients see meaningful symptom reduction within 8–12 weeks, while others require 6–9 months of multi-intervention therapy before inflammatory markers normalise. LL-37 accelerates that timeline by restoring one critical immune function that CIRS suppresses. The peptide won't fix everything, but it fills a gap that diet and binders cannot address: direct antimicrobial action and cytokine recalibration at the cellular level.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions